Investigational drug · Phase 3
Bleximenib
Also called: JNJ-75276617
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Leukemia, Leukemia, Myeloid, Acute.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Bleximenib"
First trial start
2021
May 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bleximenib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Leukemia
- Leukemia, Myeloid, Acute
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Bleximenib" as an intervention, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Pivotal-lookingRecruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT07223814 · 875 participants (planned) · Start Mar 1, 2026 · Primary completion Jun 2030
Drug: Bleximenib; Cytarabine and 2 more · For: Acute Myeloid Leukemia
Sites: Los Angeles, California; San Francisco, California; Orlando, Florida · 108 sites in all
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06852222 · 600 participants (planned) · Start Jun 4, 2025 · Primary completion Jun 22, 2029
Drug: Bleximenib; Venetoclax (VEN) and 2 more · For: Leukemia, Myeloid, Acute
Sites: Birmingham, Alabama; Goodyear, Arizona; Tucson, Arizona · 270 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04811560 · 420 participants (planned) · Start May 19, 2021 · Primary completion Dec 29, 2028
Drug: Bleximenib · For: Acute Leukemia
Sites: Duarte, California; Orange, California; San Francisco, California · 102 sites in all
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed TherapiesActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05453903 · 196 participants · Start Oct 4, 2022 · Primary completion Oct 30, 2026
Drug: Bleximenib; Venetoclax (VEN) and 3 more · For: Leukemia, Myeloid, Acute
Sites: Birmingham, Alabama; Duarte, California; Boston, Massachusetts · 32 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07295951 · 6 participants · Start Nov 18, 2025 · Primary completion Jul 21, 2026
Drug: 14C-bleximenib; bleximenib · For: Acute Lymphoblastic Leukemia; Acute Leukemias; Acute Myeloid Leukemia
Sites: Manchester, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Menin inhibitors in acute myeloid leukaemia: Mechanisms, clinical pharmacology, and emerging therapeutic strategies.
Ma C, Wang X, Wang J · Crit Rev Oncol Hematol 2026
- Menin Inhibitors in Acute Myeloid Leukemia: From Molecular Rationale to Clinical Practice.
Alati C, Molica M, Pitea M, et al. · J Pers Med 2026
- Menin inhibitors in acute leukemia: Advances and future directions.
Nasiri A, Saleh MFM, Alfayez M, et al. · Hematol Oncol Stem Cell Ther 2026
- Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy.
Zhang TY, Patel SA, Badar T · Cancers (Basel) 2026
- Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.
Agarwal G, Tonk RK, Sangwan K · Leuk Lymphoma 2026
- Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.
Ma C, Cui S, Wang J · Exp Hematol Oncol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.